title: In vitro effect of short-term exposure to two synthetic peptides, alone or in combination with clarithromycin or rifabutin, on Cryptosporidium parvum infectivity.
abstract: The viability of Cryptosporidium parvum after exposure to peptide antibiotics was studied by two different methods, a cell culture system and a double fluorogenic staining. The peptides KFFKFFKFF and IKFLKFLKFL exerted high cytotoxic effects on sporozoites, as demonstrated by cell cultures (complete inhibition after 60 min at 100 microg/ml) and flow cytometry (30% after 20 min at 100 microg/ml), but did not affect consistently the oocysts. Clarithromycin and rifabutin demonstrated less activity against sporozoites but higher activity against oocysts (30% after 180 min at 10 microg/ml). The combination between peptides and azithromycin or rifabutin exerted the highest activities.
authors.affiliation: Clinica Malattie Infettive, c/o Ospedale Regionale, Via Conca, Ancona, Italy. anconacmi@interfree.it
authors.forename: Andrea
authors.initials: A
authors.lastname: Giacometti
authors.forename: Oscar
authors.initials: O
authors.lastname: Cirioni
authors.forename: Wojciech
authors.initials: W
authors.lastname: Kamysz
authors.forename: Franciszek
authors.initials: F
authors.lastname: Kasprzykowski
authors.forename: Francesco
authors.initials: F
authors.lastname: Barchiesi
authors.forename: Maria Simona
authors.initials: MS
authors.lastname: Del Prete
authors.forename: Zbigniew
authors.initials: Z
authors.lastname: Maćkiewicz
authors.forename: Giorgio
authors.initials: G
authors.lastname: Scalise
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D017291:Clarithromycin / Q000008:administration & dosage / Q000494:pharmacology*; D016785:Cryptosporidium parvum / Q000187:drug effects* / Q000472:pathogenicity* / Q000502:physiology; D004353:Drug Evaluation, Preclinical; D004347:Drug Interactions; D005434:Flow Cytometry; D033661:Oocysts / Q000187:drug effects; D010455:Peptides / Q000008:administration & dosage / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*; D017828:Rifabutin / Q000008:administration & dosage / Q000494:pharmacology*; D034101:Sporozoites / Q000187:drug effects
chemical_list: D010455:Peptides; D017828:Rifabutin; D017291:Clarithromycin